

Jarushka Naidoo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4057376/jarushka-naidoo-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

7,394
citations

41
h-index

85
g-index

111
ext. papers

10,875
ext. citations

7.3
avg, IF

5.76
L-index

#	Paper	IF	Citations
100	Immune-related adverse events and the balancing act of immunotherapy.. <i>Nature Communications</i> , 2022 , 13, 392	17.4	18
99	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101308	2.2	42
98	Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC.. <i>Cancer Treatment Reviews</i> , 2022 , 104, 102350	14.4	2
97	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.. <i>Lung Cancer</i> , 2022 , 166, 84-93	5.9	0
96	Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.. <i>Cancer Immunology, Immunotherapy</i> , 2022 , 1	7.4	0
95	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102378	14.4	4
94	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3978-3992	2.2	12
93	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. <i>Lung Cancer: Targets and Therapy</i> , 2021 , 12, 123-131	2.9	1
92	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101440	2.2	55
91	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 860-867	8.9	118
90	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1030-1041	8.9	26
89	Immune-Related Adverse Events and Efficacy-The More It Hurts, the Better It Works?-Reply. <i>JAMA Oncology</i> , 2021 , 7, 945	13.4	
88	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events 2021 , 9,		58
87	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors 2021 , 9,		20
86	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes 2021 , 9,		12
85	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021 , 27, 2571-2583	12.9	5
84	Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. <i>Journal of Dermatological Treatment</i> , 2021 , 1-5	2.8	2

83	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021 , 596, 126-132	50.4	40
82	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers 2021 , 9,		6
81	Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. <i>Oncologist</i> , 2021 , 26, e1822-e1832	5.7	4
80	Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. <i>Cancer Investigation</i> , 2021 , 39, 789-796	2.1	2
79	Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100220	1.4	0
78	Non-Rheumatic Immune-Related Adverse Events 2021 , 191-253		
77	4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs. <i>Journal of Clinical and Translational Science</i> , 2020 , 4, 73-73	0.4	
76	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. <i>Current Oncology Reports</i> , 2020 , 22, 56	6.3	9
75	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	1888	0
74	Principles of Immunotherapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020 , 30, 187-198	3.1	8
73	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management 2020 , 8,		12
72	Chronic immune checkpoint inhibitor pneumonitis 2020 , 8,		17
71	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, e435-e444	4.9	21
70	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 332-338	2.4	81
69	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1327-1337	12.9	46
68	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma 2020 , 8,		5
67	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 230-241	7.3	112
66	Information Visualization Platform for Postmarket Surveillance Decision Support. <i>Drug Safety</i> , 2020 , 43, 905-915	5.1	2

65	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100074	1.4	4
64	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nature Cancer</i> , 2020 , 1, 99-111	15.4	67
63	Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, e169-e170	4.9	9
62	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020 , 38, 576-583	2.2	71
61	A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities. <i>Oncologist</i> , 2020 , 25, e1589-e1592	5.7	0
60	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , 2020 , 21, e398-e404	21.7	35
59	Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer. <i>JCO Oncology Practice</i> , 2020 , 16, 462-463	2.3	0
58	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020 , 6, 1952-1956	13.4	79
57	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer 2020 , 8,		40
56	Lung cancer and family-centered concerns. <i>Supportive Care in Cancer</i> , 2020 , 28, 497-505	3.9	1
55	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, e31-e43	10.2	48
54	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019 , 115, 854-868	9.9	167
53	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019 , 570, 385-389	50.4	339
52	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2738-2745	2.2	82
51	Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, e470-e479	4.9	42
50	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019 , 9, 530	5.3	22
49	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019 , 15, e825-e834	3.1	18
48	An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition. <i>Journal of Clinical Investigation</i> , 2019 , 129, 75-77	15.9	1

47	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4305-4315	15.9	47
46	A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 712-720	7.3	44
45	Management of Immunotherapy-Related Toxicities, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 255-289	7.3	246
44	Successful Treatment of Scar Pain with Scrambler Therapy. <i>Cureus</i> , 2019 , 11, e5903	1.2	1
43	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 2019 , 7, 40		28
42	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 494-502	8.9	64
41	Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019 , 79, 1204-1213	10.1	50
40	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019 , 79, 1214-1225	10.1	117
39	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1976-1986	59.2	865
38	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 916-925	4	162
37	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 553-557	5.3	89
36	Frequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918778297	5.4	7
35	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 46	5.4	9
34	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. <i>Cancer Immunology Research</i> , 2018 , 6, 888-899	12.5	60
33	A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6538-6538	2.2	6
32	2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. <i>Journal of Clinical and Translational Science</i> , 2018 , 2, 44-45	0.4	78
31	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. <i>Chest</i> , 2018 , 154, 1416-1423	5.3	111
30	Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1930-1939	8.9	160

29	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series 2018 , 6, 104		35
28	Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 467-472	7.3	8
27	Preoperative contralateral lung radiation dose is associated with postoperative pulmonary toxicity in patients with locally advanced non-small cell lung cancer treated with trimodality therapy. <i>Practical Radiation Oncology</i> , 2018 , 8, e239-e248	2.8	
26	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017 , 22, 627-630	5.7	49
25	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017 , 7, 264-276	24.4	491
24	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 43-50	2.4	248
23	Reply to M. Nishino et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1629-1630	2.2	1
22	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 709-717	2.2	587
21	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. <i>PLoS ONE</i> , 2017 , 12, e0182665	3.7	35
20	The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 615-625	0.6	6
19	Pneumonitis From Anti-PD-1/ PD-L1 Therapy. <i>Oncology</i> , 2017 , 31, 739-46, 754	1.8	22
18	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016 , 102, 21-27	5.9	10
17	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016 , 17, e121-e129	4.9	83
16	Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 537-44	8.9	28
15	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. <i>Clinical Cancer Research</i> , 2016 , 22, 3618-29	13.9	242
14	KRAS-Mutant Lung Cancers in the Era of Targeted Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 893, 155-178	3.6	18
13	Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016 , 11, e0146063	3.7	15
12	What does the future hold for immunotherapy in cancer?. <i>Annals of Translational Medicine</i> , 2016 , 4, 177	3.2	8

11	Immune-Related Adverse Events From Immune Checkpoint Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 100, 242-51	6.1	66
10	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016 , 4, 383-9	12.5	199
9	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016 , 37, 771-782	3.9	8
8	Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. <i>Cancer</i> , 2015 , 121, 2078-82	6.4	12
7	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. <i>Cancer</i> , 2015 , 121, 3212-3220	6.4	119
6	Emerging immunotherapy strategies in breast cancer. <i>Immunotherapy</i> , 2014 , 6, 195-209	3.8	22
5	Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. <i>Cancer Immunology Research</i> , 2014 , 2, 127-32	12.5	104
4	Immune checkpoint blockade. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 585-600	3.1	57
3	Should patients with extrapulmonary small-cell carcinoma receive prophylactic cranial irradiation?. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1215-21	8.9	26
2	An Irish breast cancer survivorship study: Are we meeting our patients needs?. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20687-e20687	2.2	
1	Should patients with extrapulmonary small cell carcinoma receive prophylactic cranial irradiation? An Irish experience.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2609-2609	2.2	